177 related articles for article (PubMed ID: 15988811)
41. Spot urine concentrations of type I collagen cross-linked N-telopeptides and deoxypyridinoline in psoriatic arthritis.
Al-Awadhi AM; Olusi SO; Al-Zaid NS; George S; Sugathan TN
Clin Rheumatol; 1999; 18(6):450-4. PubMed ID: 10638769
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
43. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
Bettica P; Bevilacqua M; Vago T; Masino M; Cucinotta E; Norbiato G
J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Sasada S; Okamoto N; Morishita N; Shiroyama T; Otsuka T; Miyamoto N; Taira K; Daga H; Takeda K; Hirashima T
Anticancer Res; 2015 Jul; 35(7):3987-93. PubMed ID: 26124346
[TBL] [Abstract][Full Text] [Related]
46. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
47. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
Samani KK; Brazier M; Mathiot C; Kamel S; Jamart J; Jaubert J; Blanc M; Azaïs I; Facon T; Leleu X
Ann Hematol; 2005 Jan; 84(1):19-24. PubMed ID: 15338198
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
[TBL] [Abstract][Full Text] [Related]
50. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.
Huang J; Gu T; Ying J
Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013
[TBL] [Abstract][Full Text] [Related]
51. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
[TBL] [Abstract][Full Text] [Related]
52. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
[TBL] [Abstract][Full Text] [Related]
53. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.
Pecherstorfer M; Zimmer-Roth I; Schilling T; Woitge HW; Schmidt H; Baumgartner G; Thiébaud D; Ludwig H; Seibel MJ
J Clin Endocrinol Metab; 1995 Jan; 80(1):97-103. PubMed ID: 7829646
[TBL] [Abstract][Full Text] [Related]
54. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
55. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
[TBL] [Abstract][Full Text] [Related]
56. N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases.
Kaira R; Murakami H; Kaira K; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Yamamoto N
Int J Clin Oncol; 2010 Oct; 15(5):484-8. PubMed ID: 20556457
[TBL] [Abstract][Full Text] [Related]
57. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
[TBL] [Abstract][Full Text] [Related]
58. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
59. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
60. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
